What's Your Potential Cancer Risk?

The CDC Predicts that Cancer will be the leading cause of death in the United States by the year 2020. And according to the American Cancer Society,1 in 3 people will have cancer in their lifetimes.

Why Get Tested?

Finding early indicators may give you the information you need to pursue important cancer screenings and/or adopt lifestyle changes that could lower your risk of developing cancer. Cancer, if caught early, can be beaten. The choice to act is yours.

Take Action.

Talk to your doctor about your personal cancer risk and ask him/her if our tests may be right for you.

1. Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 2010;126:1177–1186.

2. Chao S, Ying J, Liew G, et al. Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study Journal of Experimental & Clinical Cancer Research : CR. 2013;32(1):44-50.

3. Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008;63:228-233.

4. Massion PP, Healey GF, Peek LJ, et al. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer Journal of Thoracic Oncology 2017; 12 (3): 578 – 584

5. Lam, S., Boyle, P., Healey, G. et al, EarlyCDT-Lung: an immunobio-marker test as an aid to early detection of lung cancer. Cancer Prev Res. 2011;4:1126–1134

6. Melander O, Maisel AS, Almgren P, et al. Plasma Proneurotensin and Incidence of Diabetes, Cardiovascular Disease, Breast Cancer, and Mortality. JAMA. 2012;308(14):1469-1475.

7. Melander O, Orho-MelanderM, Manjer J, et al. Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk. Journal of Clinical Oncology 2015; 33 (24): 2632-2638.

8. Melander O, Belting M, Manjer J, et al. Validation of Plasma Proneurotensin as a Novel Biomarker for the Prediction of Incident Breast Cancer. Cancer Epidemiol Biomarkers Prev 2014; 23 (8):1672-1676

9. Catalona WJ, Partin AW, Sanda MG, et al. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. The Journal of urology. 2011;185(5):1650-1655.

10. Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of urology. 2015;193(4):1163-1169

11. Huang YQ, Sun T, Zhong WD, et al. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol 2014;2(4):343-350

For more information on these tests visit www.mycancerisk.info

1.855.420.7140

STAGE ZERO LIFE SCIENCES

8751 Park Central Drive, Suite 200
Richmond, VA 23227

IDL-430.1

MyCancerRisk™

Information is Your First Step to Empowerment

Learn more about your cancer risk with blood-based, biomarker tests that can help you and your doctor make informed decisions about your health.

ColonSentry®

ColonSentry, is a proprietary liquid biopsy test that uses advanced gene expression technology for the early identification of Colorectal Cancer (CRC) in average risk patients.[1,2]

- ColonSentry requires a simple blood draw that can be performed at your annual exam.

- ColonSentry requires no fasting, dietary restrictions, or special instructions.

- ColonSentry does not require you to provide or handle a stool sample.

EarlyCDT®-Lung

EarlyCDT-Lung measures seven auto-antibodies to aid in the detection of lung cancer.

- EarlyCDT-Lung can detect lung cancer-associated autoantibodies 4 years or more before diagnosis.[5]

- EarlyCDT-Lung can be used in conjunction with low dose CT scans (LDCT) to 'rule-in' lung cancer in patients with indeterminate pulmonary nodules.[4]

-

BreastSentry™

BreastSentry measures the levels of two biomarkers, proneurotensin (pro-NT) and proenkephalin (pro-ENK), which are highly predictive of a woman's risk for developing breast cancer. Longitudinal clinical studies have shown that elevated levels of pro-NT and decreased levels of pro-ENK are strong, independent risk factors for the development of breast cancer.[6,7,8]

- BreastSentry can be used to help healthcare professionals determine a woman's risk of developing breast cancer.

- BreastSentry is especially suited for women who have dense breasts. Elevated risk scores can help physicians determine if screening with MRI or Ultrasound are indicated.

The Prostate Health Index (phi)

The Prostate Health Index (phi) is an FDA approved test that can help differentiate prostate cancer from benign conditions in men with elevated PSA.

- Men with slightly elevated PSA may undergo unnecessary prostate biopsy. Using the Prostate Health Index to stratify patients with elevated PSA may reduce exposure to complications of prostate biopsy including pain, bleeding and infection.

- *phi* measures 3 different types of PSA and is run through an algorithm to create a personalized assessment score of prostate cancer risk.[9]

- Higher *phi* values are associated with increased probability of prostate cancer, and with more aggressive disease.[9]